DIM (3,3’-di-indolylmethaan) is een natuurlijke stof die in
het zure milieu van de maag ontstaat uit indol-3-carbinol (I3C),
een verbinding uit koolsoorten, radijs en daikon.
Indol-3-carbinol is een van de typerende verbindingen in
koolsoorten die ontstaat bij het kneuzen of koken van deze
groenten. DIM heeft een gunstige invloed op het
oestrogeenmetabolisme in de lever, wat kan resulteren in hogere
concentraties van 2-hydroxymetabolieten van oestrogenen en een
gezondere verhouding tussen 2-hydroxy-oestron (2-OHE1) en
16α-hydroxy-oestron (16-OHE1). Vanwege dit effect is DIM in vele
experimentele studies bestudeerd, met name in verband met
hormoongerelateerde aandoeningen zoals borstkanker en
prostaatkanker.
Beste bezoeker, u heeft geen toegang.
Enkel (web)abonnees hebben toegang tot tijdschriftartikelen. Het webabonnement is nog in de maak.
U kunt zich wel alvast (gratis) registreren en tal van andere webartikelen raadplegen!
Auteur
Figuren
Verschenen in
Referenties
Lord RS, Bongiovanni B, Bralley JA. Estrogen metabolism and the diet-cancer connection: rationale for assessing the ratio of urinary hydroxylated estrogen metabolites. Altern Med Rev. 2002 Apr;7(2):112-29.
Bradlow HL, Sepkovic DW, Telang NT et al. Multifunctional aspects of the action of indole-3-carbinol as an antitumor agent. Ann N Y Acad Sci. 1999;889:204-13.
Zeligs MA, Brownstone PK, Sharp ME et al. Managing Cyclical Mastalgia with Absorbable Diindolylmethane: A Randomized, Placebo-controlled Trial. JANA. 2005; 7(3): 5-14.
Dalessandri KM, Firestone GL, Fitch MD et al. Pilot study: effect of 3,3'-diindolylmethane supplements on urinary hormone metabolites in postmenopausal women with a history of early-stage breast cancer. Nutr Cancer. 2004;50(2):161-7.
Falk RT, Brinton LA, Dorgan JF, Fuhrman BJ, Veenstra TD, Xu X, Gierach GL. Relationship of serum estrogens and estrogen metabolites to postmenopausal breast cancer risk: a nested case-control study. Breast Cancer Res. 2013 Apr 22;15(2):R34.
Napoli N, Vattikuti S, Yarramaneni J, Giri TK, Nekkalapu S, Qualls C, Armamento-Villareal RC. Increased 2-hydroxylation of estrogen is associated with lower body fat and increased lean body mass in postmenopausal women. Maturitas. 2012 May;72(1):66-71.
Campbell KL, Westerlind KC, Harber VJ, Bell GJ, Mackey JR, Courneya KS. Effects of aerobic exercise training on estrogen metabolism in premenopausal women: a randomized controlled trial. Cancer Epidemiol Biomarkers Prev. 2007 Apr;16(4):731-9.
Rajoria S, Suriano R, Parmar PS, Wilson YL, Megwalu U, Moscatello A, Bradlow HL, Sepkovic DW, Geliebter J, Schantz SP, Tiwari RK. 3,3'-diindolylmethane modulates estrogen metabolism in patients with thyroid proliferative disease: a pilot study. Thyroid. 2011 Mar;21(3):299-304.
Sowers MR, McConnell D, Jannausch M, Buyuktur AG, Hochberg M, Jamadar DA. Estradiol and its metabolites and their association with knee osteoarthritis. Arthritis Rheum. 2006 Aug;54(8):2481-7.
Barba M, Yang L, Schünemann HJ, Sperati F, Grioni S, Stranges S, Westerlin KC, Blandino G, Gallucci M, Lauria R, Malorni L, Muti P. Urinary estrogen metabolites and prostate cancer: a case-control study and meta-analysis. J Exp Clin Cancer Res. 2009 Oct 8;28:135.
Del Priore G, Gudipudi DK, Montemarano N, Restivo AM, Malanowska-Stega J, Arslan AA. Oral diindolylmethane (DIM): pilot evaluation of a nonsurgical treatment for cervical dysplasia. Gynecol Oncol. 2010 Mar;116(3):464-7.
Castañon A, Tristram A, Mesher D, Powell N, Beer H, Ashman S, Rieck G, Fielder H, Fiander A, Sasieni P. Effect of diindolylmethane supplementation on low-grade cervical cytological abnormalities: double-blind, randomised, controlled trial. Br J Cancer. 2012 Jan 3;106(1):45-52.
Dong L, Xia S, Gao F, Zhang D, Chen J, Zhang J. 3,3'-Diindolylmethane attenuates experimental arthritis and osteoclastogenesis. Biochem Pharmacol. 2010 Mar 1;79(5):715-21.
Yu TY, Pang WJ, Yang GS. 3,3'-Diindolylmethane increases bone mass by suppressing osteoclastic bone resorption in mice. J Pharmacol Sci. 2015 Jan;127(1):75-82.
Ziegler RG, Fuhrman BJ, Moore SC, Matthews CE. Epidemiologic studies of estrogen metabolism and breast cancer. Steroids. 2015 Jul;99(Pt A):67-75.
Zhang WW, Feng Z, Narod SA. Multiple therapeutic and preventive effects of 3,3'-diindolylmethane on cancers including prostate cancer and high grade prostatic intraepithelial neoplasia. J Biomed Res. 2014 Sep;28(5):339-48.
Gong Y, Firestone GL, Bjeldanes LF. 3,3'-diindolylmethane is a novel topoisomerase IIalpha catalytic inhibitor that induces S-phase retardation and mitotic delay in human hepatoma HepG2 cells. Mol Pharmacol. 2006 Apr;69(4):1320-7. Epub 2005 Dec 29.
Hesterman EV, Brown M. Agonist and chemopreventative ligands induce differential transcriptional cofactor recruitment by aryl hydrocarbon receptor. Mol Cell Biol. 2003 Nov;23(21):7920-5.
Mulvey L, Chandrasekaran A, Liu K et al. Interplay of genes regulated by estrogen and diindolylmethane in breast cancer cell lines. Mol Med. 2007 Jan-Feb;13(1-2):69-78.
Jernström H, Klug TL, Sepkovic DW, Bradlow HL, Narod SA. Predictors of the plasma ratio of 2-hydroxy-oestrone to 16alpha-hydroxy-oestrone among pre-menopausal, nulliparous women from four ethnic groups. Carcinogenesis. 2003May;24(5):991-1005.
Kotsopoulos J, Zhang S, Akbari M, Salmena L, Llacuachaqui M, Zeligs M, Sun P, Narod SA. BRCA1 mRNA levels following a 4-6-week intervention with oral 3,3'-diindolylmethane. Br J Cancer. 2014 Sep 23;111(7):1269-74.
Le HT, Schaldach CM, Firestone GL et al. Plant-derived 3,3'-Diindolylmethane is a strong androgen antagonist in human prostate cancer cells.J Biol Chem. 2003 Jun 6;278(23):21136-45.
Paltsev M, Kiselev V, Muyzhnek E, Drukh V, Kuznetsov I, Pchelintseva O. Safety and tolerability of DIM-based therapy designed as personalized approach to reverse prostatic intraepithelial neoplasia (PIN). EPMA J. 2014 Oct 8;5(1):18.
Garikapaty VP, Ashok BT, Tadi K, Mittelman A, Tiwari RK. 3,3'-Diindolylmethane downregulates pro-survival pathway in hormone independent prostate cancer. Biochem Biophys Res Commun. 2006 Feb 10;340(2):718-25.
Kong D, Sethi S, Li Y, Chen W, Sakr WA, Heath E, Sarkar FH. Androgen receptor splice variants contribute to prostate cancer aggressiveness through induction of EMT and expression of stem cell marker genes. Prostate. 2015 Feb;75(2):161-74.
McGuire KP, Ngoubilly N, Neavyn M et al. 3,3'-diindolylmethane and paclitaxel act synergistically to promote apoptosis in HER2/Neu human breast cancer cells. J Surg Res. 2006 May 15;132(2):208-13.
Rahman KM, Ali S, Aboukameel A et al. Inactivation of NF-kappaB by 3,3'-diindolylmethane contributes to increased apoptosis induced by chemotherapeutic agent in breast cancer cells. Mol Cancer Ther. 2007 Oct;6(10):2757-65. Epub 2007 Oct 3.
Riby JE, Xue L, Chatterji U et al. Activation and potentiation of interferon-gamma signaling by 3,3'-diindolylmethane in MCF-7 breast cancer cells. Mol Pharmacol. 2006 Feb;69(2):430-9. Epub 2005 Nov 2.
Singh-Gupta V, Banerjee S, Yunker CK, Rakowski JT, Joiner MC, Konski AA, Sarkar FH, Hillman GG. B-DIM impairs radiation-induced survival pathways independently of androgen receptor expression and augments radiation efficacy in prostate cancer. Cancer Lett. 2012 May 1;318(1):86-92.
Fan S, Meng Q, Xu J, Jiao Y, Zhao L, Zhang X, Sarkar FH, Brown ML, Dritschilo A, Rosen EM. DIM (3,3'-diindolylmethane) confers protection against ionizing radiation by a unique mechanism. Proc Natl Acad Sci U S A. 2013 Nov 12;110(46):18650-5.
Wu TY, Huang Y, Zhang C, Su ZY, Boyanapalli S, Khor TO, Wang H, Lin H, Gounder M, Kagan L, Androulakis IP, Kong AN. Pharmacokinetics and pharmacodynamics of 3,3'-diindolylmethane (DIM) in regulating gene expression of phase II drug metabolizing enzymes. J Pharmacokinet Pharmacodyn. 2015 Aug;42(4):401-8.
Reed GA, Sunega JM, Sullivan DK, Gray JC, Mayo MS, Crowell JA, Hurwitz A. Single-dose pharmacokinetics and tolerability of absorption-enhanced 3,3'-diindolylmethane in healthy subjects. Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2619-24.
Heath EI, Heilbrun LK, Li J, Vaishampayan U, Harper F, Pemberton P, Sarkar FH. A phase I dose-escalation study of oral BR-DIM (BioResponse 3,3'-Diindolylmethane) in castrate-resistant, non-metastatic prostate cancer. Am JTransl Res. 2010 Jul 23;2(4):402-11.
Anderton MJ, Manson MM, Verschoyle R, Gescher A, Steward WP, Williams ML,Mager DE. Physiological modeling of formulated and crystalline 3,3'-diindolylmethane pharmacokinetics following oral administration in mice.Drug Metab Dispos. 2004 Jun;32(6):632-8.
